Clinical trials on human participants generate data on dosage, safety and efficacy. They are conducted only after health authority or ethics committee approval in the country where approval of the therapy is sought. Approval means only that the trial may be conducted, not that the therapy is safe or effective.
The draft amendment exists because manufacturing licences for antimicrobial products have reportedly been granted without adequate scrutiny of bioavailability, bioequivalence and stability. The ministry says substandard or ineffective antimicrobials can drive antimicrobial resistance (AMR), so it proposes bringing antimicrobials within the new drug framework.PIB

Key facts
| Nodal ministry | Ministry of Health and Family Welfare, Government of IndiaPIB |
|---|---|
| Parent law | Drugs and Cosmetics Act, 1940, with the Drugs and Cosmetics Rules, 1945 |
| Draft amendment | G.S.R. 983 (E) dated 6 November 2026, proposing to add antimicrobials to the definition of 'New Drug' under Rule 2(1)(w)(v)PIB |
| Central approval step | Under the proposal, manufacturers would need Central Licensing Authority permission before applying to the State Licensing Authority for a manufacturing licence.PIB |
| Consultation period | 30 days from the date copies of the Gazette are made available to the publicPIB |
| Regulator | Central Drugs Standard Control Organisation (CDSCO)cdsco.gov.in |
| Registration requirement | Trials must be pre-registered in the Clinical Trials Registry - India before enrolling participants |
Key features and how it works
- Defines what counts as a 'new drug' (Rule 2(1)(w)); the draft amendment adds antimicrobials to this definition at sub-clause (v).PIB
- Under the proposal, a two-step licensing route applies: Central Licensing Authority permission first, then the manufacturing licence from the State Licensing Authority.PIB
- The Drugs Controller General of India heads CDSCO and approves clinical trials and new drugs; CDSCO has zonal offices and regulates clinical trials.
- Clinical trials in India must be publicly documented in the Clinical Trials Registry - India, which the Central Drugs Standard Control Organisation has required since 2009 before enrolment.
Static GK
- Central Drugs Standard Control Organisation (CDSCO): responsible for drug approvals, conduct of clinical trials, drug standards and control over the quality of imported drugs.cdsco.gov.in
- Drugs Controller General of India (DCGI): head of CDSCO, responsible for approval of licences for specified categories of drugs, including blood products, IV fluids, vaccines and sera.
- Clinical Trials Registry - India (CTRI): the government's official clinical trial registry, established by the National Institute of Medical Statistics of the Indian Council of Medical Research on 20 July 2007.
- Drugs and Cosmetics Rules, 1945: rules under the Drugs and Cosmetics Act, 1940 that classify drugs into schedules; Schedule Y contains requirements and guidelines for clinical trials.
- Pharmacovigilance Programme of India: tracks reports of harm from the use of drugs.
Achievements
- The draft amendment proposes a central permission step before manufacturers apply for antimicrobial manufacturing licences. The ministry expects this to strengthen central regulatory oversight and help ensure product quality, safety and efficacy.PIB
- The CTRI registration requirement has been reported to help prevent selective reporting of results and duplication of research.
- Trial rules were reformed after the 2013 Supreme Court case Swasthya Adhikar Manch v. Union of India, to make clinical trials more ethical.
Challenges
- In 2015, the government told the Supreme Court that a lack of specific penalties meant it could only halt the HPV vaccine trials and issue warnings.
- Critics say the Indian drug regulator's approval standards are lower than those of the US FDA and the EU's EMA, and that enforcement is weak.
- Registry data quality is a concern, as users register their own trials and the form lacks precision, so errors enter the record.
Way forward
- Finalise the amendment only after the 30-day consultation, with stakeholder objections and suggestions considered by the Central Government.PIB
- Clear penalty provisions for clinical trial violations, which the Drugs and Cosmetics Act currently lacks.
Timeline
19 November 2026
Draft amendment proposed to add antimicrobials to the 'new drug' definition under Rule 2(1)(w)(v), requiring central permission before state manufacturing licences, to curb antimicrobial resistance.
Read the story6 November 2026
Draft amendment G.S.R. 983 (E) issued proposing antimicrobials be included in the 'new drug' definition under Rule 2(1)(w)(v) of the NDCT Rules, 2019.PIB
15 June 2009
CDSCO makes trial registration mandatory, with pre-registration required before enrolment.
20 July 2007
Clinical Trials Registry - India established by the Indian Council of Medical Research.
1945
Drugs and Cosmetics Rules, 1945 framed under the Act.
1940
Drugs and Cosmetics Act, 1940 passed, originally known as the Drug Act, following the Chopra Committee recommendations.
Every new story on this subject is added here automatically.
Frequently asked questions
What does the 2026 draft amendment change in the NDCT Rules, 2019?
It proposes to include antimicrobials in the definition of 'new drug' under Rule 2(1)(w)(v), so manufacturers would need permission from the Central Licensing Authority before applying for a State Licensing Authority manufacturing licence.PIB
How long is the public consultation on the draft?
Objections and suggestions can be submitted within 30 days from the date copies of the Gazette containing the draft rules are made available to the public.PIB
Which ministry issued the draft amendment?
The Ministry of Health and Family Welfare, Government of India, issued the draft amendment.PIB
Is clinical trial registration mandatory in India?
Yes, CDSCO has required trials to be pre-registered in the Clinical Trials Registry - India before enrolling participants since 2009.
GS paper mapping
- GS-2Health: government policies and interventions for health; regulation of drugs and medical products
- GS-2Governance: statutory, regulatory and quasi-judicial bodies (CDSCO, DCGI)
- GS-3Health and disease: antimicrobial resistance and the One Health approach
- GS-2International relations: India's commitments under the G20 New Delhi Leaders' Declaration
Sources
Every fact on this page was checked against these pages.

